Update on the male hormonal contraceptive agents.
There remains a need for new acceptable and effective male contraceptives to increase the choice for couples throughout the world. There have been no recent advances in available male contraceptive methods although a number of promising approaches have been identified, of which the hormonal approach is currently undergoing clinical investigation. In recent years the pace of research in this area has quickened significantly with increasing interest and now investment by the pharmaceutical industry. This is vital if the work undertaken so far by the public sector is to be transformed into a commercial reality. The hormonal approach is based on suppression of pituitary gonadotropin secretion resulting in a reversible reduction in spermatogenesis with azoospermia in all men being the ultimate aim. Without stimulation by luteinising hormone from the pituitary, testicular testosterone production also ceases. Therefore, androgen administration to restore physiological levels is an essential component of all male hormonal contraceptive regimes. Male hormonal contraceptives can consist of testosterone alone, or either a progestogen or gonadotropin-releasing hormone antagonist with 'add-back' testosterone. This article reviews the current state of progress in this field.
MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, University of Edinburgh, UK.
Melanie
M
Walton
Richard A
RA
Anderson
D000728:Androgens / Q000627:therapeutic use; D003272:Contraceptive Agents, Male / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D045167:Progesterone Congeners / Q000627:therapeutic use
D000728:Androgens; D003272:Contraceptive Agents, Male; D006728:Hormones; D045167:Progesterone Congeners; D007987:Gonadotropin-Releasing Hormone